Literature DB >> 15294979

Human papillomavirus type-16 virus-like particles activate complementary defense responses in key dendritic cell subpopulations.

Rongcun Yang1, Francisco Martinez Murillo, Ken-Yu Lin, William H Yutzy, Satoshi Uematsu, Kiyoshi Takeda, Shizuo Akira, Raphael P Viscidi, Richard B S Roden.   

Abstract

Human papillomavirus type-16 (HPV16) L1 virus-like particles (VLPs) activate dendritic cells (DCs) and induce protective immunity. In this study, we demonstrate, using global gene expression analysis, that HPV16 VLPs produce quite distinct innate responses in murine splenic DC subpopulations. While HPV16 VLPs increase transcription of IFN-gamma and numerous Th1-related cytokines and chemokines in CD8alpha(+)CD11c(+) DCs, CD4(+)CD11c(+) DCs up-regulate only type I IFN and a different set of Th2-associated cytokines and chemokines. Type I IFN, but not IFN-gamma, potentiates humoral immunity, notably production of VLP-specific IgG2a. However, HPV16 VLP-stimulated IL-12 production by CD8alpha(+)CD11c(+) DCs is augmented by autocrine IFN-gamma signaling. Thus, before adaptive immunity, HPV16 VLPs signal complementary defense responses in key DC subpopulations, indicating specialized DC lineages with predetermined polarization.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15294979     DOI: 10.4049/jimmunol.173.4.2624

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.

Authors:  L Buonaguro; M L Tornesello; M Tagliamonte; R C Gallo; L X Wang; R Kamin-Lewis; S Abdelwahab; G K Lewis; F M Buonaguro
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  HPV - immune response to infection and vaccination.

Authors:  Margaret Stanley
Journal:  Infect Agent Cancer       Date:  2010-10-20       Impact factor: 2.965

Review 3.  Epithelial cell responses to infection with human papillomavirus.

Authors:  Margaret A Stanley
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

4.  Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis.

Authors:  Irena Hočevar-Boltežar; Mojca Matičič; Maja Sereg-Bahar; Nina Gale; Mario Poljak; Boštjan Kocjan; Miha Zargi
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-26       Impact factor: 2.503

5.  Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.

Authors:  Christina Schellenbacher; Richard Roden; Reinhard Kirnbauer
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

6.  A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.

Authors:  Katharina Slupetzky; Ratish Gambhira; Timothy D Culp; Saeed Shafti-Keramat; Christina Schellenbacher; Neil D Christensen; Richard B S Roden; Reinhard Kirnbauer
Journal:  Vaccine       Date:  2006-11-29       Impact factor: 3.641

Review 7.  HPV and the Risk of HIV Acquisition in Women.

Authors:  Romaniya Zayats; Thomas T Murooka; Lyle R McKinnon
Journal:  Front Cell Infect Microbiol       Date:  2022-02-10       Impact factor: 5.293

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.